Republic Healthcare Limited (8357) AI Stock Analysis

1 Followers

Republic Healthcare Limited

(HKEX:8357)

Select Model

Rating:51Neutral

Price Target:HKD 0.17▲(0.58% Upside)

Action:reiterated

Date:10/27/26

The score is held back primarily by weak financial performance—deepening losses and negative operating/free cash flow despite revenue growth—indicating elevated execution and funding risk. Technicals are a clear offset, with the stock in an uptrend and positive momentum signals. Valuation remains unattractive because the company is loss-making and there is no dividend yield support.

Positive Factors

Revenue ReboundTTM revenue growth of 27.8% shows the business can regain demand and expand its top line after a weaker period. If the rebound persists, a larger revenue base could improve operating leverage and support recovery efforts, although profitability must still follow.

Negative Factors

Deepening LossesNegative gross profit and a net margin near -40% indicate that current revenue is not covering the underlying cost structure. Persistent losses reduce internal funding capacity, weaken resilience, and make a durable earnings recovery dependent on significant operating improvement.

Republic Healthcare Limited (8357) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 91.73M
Dividend Yield: ―
Average Volume (3M): 1.59M
Price to Earnings (P/E): -3.5
Beta (1Y): 0.32
Revenue Growth: 9.57%
EPS Growth: -179.66%
Country: Hong Kong
Employees: 35
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

Republic Healthcare Limited Business Overview & Revenue Model

Company Description

Republic Healthcare Limited, a Singaporean primary healthcare enterprise, furnishes an array of medical services, encompassing consultations, diagnostic examinations, and therapeutic interventions. The company delivers diverse treatment solutions for...

Republic Healthcare Limited Financial Statement Overview

Summary

Revenue rebounded strongly in the TTM period (+27.8%), but profitability and cash generation deteriorated materially. Gross profit turned negative, losses widened (net margin around -40%), and operating/free cash flow moved to significant outflows, raising near-term operating and funding pressure despite only moderate leverage.

Income Statement

18Very Negative

Balance Sheet

55Neutral

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.32M	7.84M	9.23M	10.28M	9.04M	13.37M
Gross Profit	-793.32K	-23.92K	2.26M	2.70M	1.89M	9.13M
EBITDA	-1.43M	-1.76M	319.04K	29.34K	-387.88K	962.89K
Net Income	-4.16M	-2.96M	-178.16K	-855.12K	-1.48M	-997.93K
Balance Sheet
Total Assets	12.87M	16.14M	14.48M	15.64M	16.32M	19.27M
Cash, Cash Equivalents and Short-Term Investments	5.40M	6.85M	11.52M	11.93M	11.83M	14.27M
Total Debt	3.42M	5.03M	858.22K	961.16K	810.47K	1.55M
Total Liabilities	4.90M	6.59M	1.93M	2.89M	2.30M	3.67M
Stockholders Equity	7.96M	9.55M	12.55M	12.75M	14.12M	15.59M
Cash Flow
Free Cash Flow	-3.13M	-3.12M	51.27K	806.24K	-1.16M	-1.13M
Operating Cash Flow	-1.79M	-1.90M	125.07K	899.91K	-734.46K	-510.07K
Investing Cash Flow	-1.71M	-2.22M	-93.94K	831.49K	-987.23K	-1.56M
Financing Cash Flow	-1.17M	-813.99K	-531.65K	-587.62K	-689.73K	2.28M

Republic Healthcare Limited Technical Analysis

Technical Analysis SentimentNeutral

Last Price0.17

Price Trends

50DMA0.16Positive

100DMA0.14Positive

200DMA0.14Positive

Market Momentum

MACD0.01Positive

RSI41.03Neutral

STOCH15.52Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8357, the sentiment is Neutral. The current price of 0.17 is below the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.16, and above the 200-day MA of 0.14, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 41.03 is Neutral, neither overbought nor oversold. The STOCH value of 15.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:8357.

Republic Healthcare Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

HK:8357 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:3309	76Outperform	HKD 1.16B	11.52	5.57%	2.12%	4.75%	―
HK:2135	56Neutral	HKD 50.69M	3.25	12.17%	―	36.68%	―
HK:1846	52Neutral	HKD 671.52M	270.13	0.20%	2.12%	20.54%	-96.74%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:8357	51Neutral	HKD 124.80M	-3.45	-47.53%	―	9.57%	-179.66%
HK:3886	41Neutral	HKD 1.06B	78.09	0.48%	1.10%	-3.26%	―
HK:8307	37Underperform	HKD 59.51M	63.44	19.79%	―	6.13%	―

* Healthcare Sector Average

Performance Comparison

HK:8357 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:8357	Republic Healthcare Limited	0.17	0.02	13.07%
HK:1846	EuroEyes International Eye Clinic Limited	2.08	-1.16	-35.86%
HK:2135	Raily Aesthetic Medicine International Holdings Limited	0.09	-0.04	-31.85%
HK:3309	C-MER Eye Care Holdings Limited	0.97	-0.80	-45.32%
HK:3886	Town Health International Medical Group Ltd.	0.16	-0.09	-36.19%
HK:8307	Medicskin Holdings Ltd.	0.15	-0.04	-22.28%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026

Republic Healthcare Limited AI Stock Analysis